细胞色素P4502C9-Leu359基因变异与华法林抗凝治疗研究
Prevention and Treatment of Cardio-Cerebral-Vascular Disease（2001）
Abstract
目的研究细胞色素P4502C9-Leu359基因变异与华法林耐量和抗凝出血并发症的关系。方法对55例心脏瓣膜置换术后长期服用华法林的病人，根据华法林用量大小分组：华法林用量/体表面积≤1.5mgm2-1为G1组，＞1.5mgm2-1为G2组。利用PCR-RFLP法进行CYP2C9Leu359基因测定，同时随访出血并发症，进行比较分析。结果 G1组CYP2C9Leu359突变明显高于G2组(P＜0.05)；G1组出血发生率明显高于G2组(P＜0.05)。结论CYP2C9 Leu359突变者，华法林耐受剂量小；华法林耐量小者，容易出血。选择CYP2C9 Leu359作为基因监测有助于预测华法林的用量。
MoreTranslated text
Key words
cytochrome p4502c9 leu359,anticoagulation therapy,genetic mutation
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined